The phase 3 clinical trial is a prospective, double-blind, randomized, placebo and midazolam-controlled multicenter study, according to the report. During phase 2 clinical trials, Remimazolam was found to have a faster onset of sedation and faster patient recovery in comparison to midazolam.
The phase 3 clinical trial will include 460 patients undergoing diagnostic and therapeutic colonoscopy.
More articles on gastroenterology:
Boston Scientific CEO says medical device tax hinders industry
18 statistics on gastroenterologist habits & burnout
6 gastroenterologists making headlines – March 27, 2015
